"we were quite surprised to find there were no significant differences," says study author
.
.
plemmons and co-authors disclosed no relevant relationships with industry.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
. sign in to get notified via email when new comments are made.
.